1 QALY, Burden of Disease and Budget Impact  Jan J.V. Busschbach, Ph.D.  Erasmus MC, Rotterdam, The Netherlands  

Slides:



Advertisements
Similar presentations
Priority setting in healthcare Hareth Al-Janabi MPH, University of Birmingham, June 2010.
Advertisements

HEALTH SERVICES, DEPRIVED GROUPS AND EQUITY: UK EXPERIENCE Julian Le Grand London School of Economics.
Quality of life (Utility) Measurements In Relation to Health Economics
How do we achieve cost effective cancer treatments in the UK? Professor Peter Littlejohns Department of Public Health and Primary Care.
Value & Coverage Issue Brief Slides A Closer Look at Health Plan Coverage Policies and Approaches.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Justice and Economic Evaluation Prof. Dr. Jan Busschbach
We show that MP can be used to allocate resources to treatments within and between patient populations, using a policy-relevant example. The outcome is.
“Rational Pharmacology” and Health Economics By Alan Maynard.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
Balancing efficiency and equity in formal economic evaluation of health care. Erik Nord, Senior Researcher, Norwegian Institute of Public Health, Professor.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Developing a multi-criteria approach for drug reimbursement decision making: an initial step forward Francois Dionne- Centre for Clinical Epidemiology.
End-of-life premiums in reimbursement decision making Christopher McCabe PhD Capital Health Endowed Research Chair University of Alberta.
The relevance of Health Economics Research for the Health Policy Agenda Prof. Guillem López-Casasnovas Depart. de Economía Univ. Pompeu Fabra. Cataluña.
Valuation issues Jan Sørensen, Health Economist CAST – Centre for Applied Health Services Research and Technology Assessment University of Southern Denmark.
QALYs and Ethics Prof. dr. Jan van Busschbach 11.
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
QALYs and Ethics Is there an ethical / valid alternative?
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Barriers to Health Care & Access to Care Philip Boyle, Ph.D. Vice President, Ethics
REGIONAL DELEGATES CONFERENCE 2014 Equality Act and Mental Capacity Act.
1 Econoqualimetrics Edward Broughton, PhD., MPH Senior Economic Analyst, USAID Health Care Improvement Project, EnCompass,
Overview of the EQ-5D Purpose and origins of the descriptive system.
BIOE 301 Lecture Thirteen. HIV/AIDS Vaccine Update.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
Measurement Measuring disease and death frequency FETP India.
How can societal concerns for fairness be integrated in economic evaluations of health programs? Erik Nord, PhD, Senior Researcher, Norwegian Institute.
Tuberculosis Research of INA-RESPOND on Drug-resistant
HTA – Cost Containment or Quality Instrument? Bengt Jönsson Stockholm School of Economic.
The return of the 5 year plan Mathematical programming for allocation of health care resources David Epstein, Karl Claxton, Mark Sculpher (CHE) Zaid Chalabi.
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
Economic evaluation of drugs for rare diseases CENTRE FOR HEALTH ECONOMICS K Claxton, C McCabe, A Tsuchiya Centre for Health Economics and Department of.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
What is the relative importance of cost-effectiveness information? Results from a Discrete Choice Experiment among Swedish medical decision makers. Sandra.
Cost-effectiveness of psychotherapy for personality disorders Djøra Soeteman Viersprong Institute for Studies on Personality Disorders Erasmus Medical.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
1 The Cost Effectiveness of Treatment of Personality Disorder  Dr. Jan J.V. Busschbach  PTC De Viersprong, Erasmus MC, Rotterdam, 
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Cost Effectiveness  Jan J.V. Busschbach, Ph.D.  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
International Health Policy Program -Thailand NHA TEAM International Health Policy Program Draft report presentation for external peer review October 7,
1 Value of Information in relation to risk management  Prof. Dr. Jan J.V. Busschbach.
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Matching Analyses to Decisions: Can we Ever Make Economic Evaluations Generalisable Across Jurisdictions? Mark Sculpher Mike Drummond Centre for Health.
Age-Based Rationing?. Some Facts 1980, 1986: those over 65 consumed 29%, 31% (respectively) of health care expenditures Prediction: by 2040 elderly 21%
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
How to weight cost effectiveness in appraisal NVTAG / CVZ course: The appraisal process, work in progress 22th of April 2009 Jan van Busschbach.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group.
Fiscal aspects of health systems William Jack Georgetown University Motivated by “The fiscal sustainability of health care in Canada” Gregory Marchildon,
The determinants of change in the cost-effectiveness threshold Mike Paulden, MSc 1 James O’Mahony, PhD 2 Christopher McCabe, PhD 1 1 Department of Emergency.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
CoRPS Nice Center of Research on Psychology in Somatic diseases Quality of life and symptom assessment in long-term blood cancer survivors (chapter.
Burden of Disease and Health Economics: Friends or Foes?
Resource Allocation in Health Care
Justification treatment cost
Presentation transcript:

1 QALY, Burden of Disease and Budget Impact  Jan J.V. Busschbach, Ph.D.  Erasmus MC, Rotterdam, The Netherlands    Issue Panels – Session II Tuesday, May 22, :00 PM – 3:00 PM

Citations in PubMed

3 Health economics is not the only argument  Reimbursement decisions are a combination of arguments  Health economic  Juridical  Ethical  What are these other arguments?  Not clear in Juridical and ethics  Are other arguments important?  How can we use them?

4 What are the ‘other’ arguments?  Used when economics evaluation ‘fails’  Reimbursement of lung transplantation  No reimbursement of Viagra  First, debate about the validity of the health economics  lung transplantation: not all cost of screening / waiting list should be included  Viagra: preferences for sex (erectile functioning) can not be measured  Secondly, ad hoc arguments are used  lung transplantation: it is unethical to let someone die  Viagra: erectile dysfunction in old men is not a disease

5 Ad hoc argument repressed equity concerns  Severity of illness  Looking forwards Prospective health  lung transplantation: it is unethical to let someone die Rule of rescue Necessity of care Eric Nord  Fair innings  Looking backwards Total health  Viagra: when you get older, erectile dysfunction is not longer considered a disease in old men: you had your fair share Alan Williams

6 Person trade-off  Incorporates equity concerns in QALY  Nord / Richardson / Murray ?? persons 1 year free from disease Q 100 persons additionally 1 healthy year

7 PTO differs from TTO Susan Robinson, iHEA 2001 Also: Report Health Services Management Centre, Birmingham

Psychometrics  “If we look at TTO and PTO…  …we see that one of them is wrong”  Paul Kind, iHEA 2001 Susan Robinson, iHEA 2001

Psychometrics  “And if we look at PTO alone…  …we still see that one of them is wrong…”  Paul Kind, iHEA 2001

10 Incorporated equity in model  Weight QALY by equity  Wagstaff 1991  The higher the burden of disease  The more money we are willing to spend  The higher the QALY threshold  A floating threshold….  Might be the reason we could not find it…

11 A floating threshold

12 Drawback  The more differentiation of the threshold…  The lower the population health  If we spend all our money in curing the worst of patients…  All others die sooner…  Equity-efficiency trade-off  Wagstaff 1991

13 Several definition of burden (equity)  Fair innings  How good has it been?  Severity of illness  How bad is it now? But what if the severity of illness is a result of old age? Discriminate the old?

14  Compares loss in QALY with expected QALY  The higher the proportion  The higher the need for equity compensation Proportional short fall Prop. Short Fall = 25%Prop. Short Fall = 50%Prop. Short Fall = 60% QALY lostQALY gain t  QoL  Prop. Short Fall = 50% Now

15 Proportional short fall Intermediate position  Fair innings  Looking backwards  Total health  Severity of illness  Looking forwards  Prospective health  Proportional short fall  Intermediate Health patient A t  Prospective health patient A Birth Now Fair innings patient A

16 What can we do with it?  Better understand health policy  Why are some cost effective treatments not reimbursed  Why are some not cost effective treatment reimbursed  Cost effectiveness interact with equity  Is there indeed a shifting threshold?  Tested in policy practice

17 CE-ratio by equity

18 Burden as criteria Pronk & Bonsel, Eur J Health Econom 2004, 5:

19 Dutch Council for Public Health and Health Care (RvZ, 2006) €

20 Alternative interpretation: Budget impact….

21 Budget impact  The Third Man  Next to cost effectiveness  Next to burden (equity)  Are we more willing to pay for:  Low incidences?  Are high incidences linked to low burden?  Opposition from economists  Abandoned efficiency as primary criterion  Like burden of disease  But might be relevant for policy…. For good reasons

22 Conclusions  Efficiency / Equity trade-off  The more severe the health state The more we are willing to contribute The more money we are willing the spend  Budget impact  High incident / prevalence are suspected Possible link with burden